Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befiradol dose-finding study in painful diabetic peripheral neuropathy
2009-012123-28Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of NLX-112 in diabetic polyneuropathy (DPN) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Responder rate based on pain reduction. Started May 2009; status: completed.
02
Drugs
NLX-112
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2009-012123-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012123-28.